The FDA sent an Untitled Letter to AbbVie, Inc. of North Chicago, Ill., over a direct-to-consumer (DTC) television ad for Ubrelvy (ubrogepant) tablets, for oral use.  In the Aug. 29 Untitled Letter FDA’s Office of Prescription Drug Promotion (OPDP) alleged the ad made false or misleading representations and suggestions about the efficacy of Ubrelvy. “These violations are con... Read More